<DOC>
	<DOCNO>NCT00629278</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know regimen combination chemotherapy give together trastuzumab effective treat breast cancer . PURPOSE : This randomized phase III trial compare two different regimen combination chemotherapy give together trastuzumab see well work treat woman HER2-positive stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Trastuzumab Treating Women With Stage I , Stage II , Stage III HER2-Positive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate 3 month trastuzumab ( Herceptin® ) administer accord Finnish protocol ( 9-weekly administration ) inferior 12 month ( 18 three-weekly administration ) standard chemotherapy protocol , term disease-free survival , patient HER2-positive early breast cancer . - To determine overall survival patient treat regimen . Secondary - To determine failure rate 2 year , calculate cumulative incidence relapse , contralateral breast cancer ( exclude situ carcinoma ) , death cause , treatment withdrawal due toxicity therapy . - To determine incidence cardiac event ( define decrease ejection fraction ( EF ) 15 % basal value , decrease 10 % EF absolute value 50 % , symptomatic cardiac failure , cardiac side effect grade 2 accord NCI CTCAE v.3 . OUTLINE : This multicenter study . Patients stratify accord nodal status ( positive v negative ) , hormone-receptor status ( estrogen receptor-positive v progesterone receptor-positive disease ) , Regional Coordinating Center . Patients randomize 1 2 treatment arm . - Arm I ( standard long-term adjuvant treatment-12 month ) : Patients receive chemotherapy comprise either doxorubicin hydrochloride IV cyclophosphamide IV epirubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients receive paclitaxel IV 3 hour docetaxel* IV 1 hour concurrent trastuzumab ( Herceptin® ) IV 90 minute . Treatment repeat every 21 day 4 course . NOTE : *Patients &lt; 65 year old receive high dose docetaxel patient ≥ 65 year old receive low dose docetaxel . After completion chemotherapy concurrent trastuzumab , patient receive trastuzumab IV 30-60 minute monotherapy every 21 day 14 course absence disease progression unacceptable toxicity . - Arm II ( experimental short-term adjuvant treatment-3 month ) : Patients receive docetaxel** IV day 1 . Treatment repeat every 21 day 3 course . Patients also receive trastuzumab IV 30-60 minute day 1 . Treatment repeat weekly 9 week ( 9 dos ) . Within 21 day completion docetaxel therapy , patient receive fluorouracil IV , epirubicin hydrochloride IV , cyclophosphamide IV day 1 . Treatment repeat every 21 day 3 course . NOTE : **Patients &lt; 65 year old receive high dose docetaxel patient ≥ 65 year old receive low dose docetaxel . In arm , patient treat conservative surgery 4 positive axillary node undergo radiotherapy within 8 week completion chemotherapy . Patients enrol arm I undergo radiotherapy concurrently trastuzumab . Patients hormone receptor-positive tumor ( i.e. , estrogen receptor and/or progesterone receptor-positive tumor ) also receive hormonal treatment completion chemotherapy . Patients enrol arm I receive hormonal therapy concurrently trastuzumab . Premenopausal patient receive monthly luteinizing-hormone releasing-hormone agonist 2 year plus daily tamoxifen citrate 5 year . Post-menopausal patient receive aromatase inhibitor daily 5 year . After completion study therapy , patient follow 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis infiltrate primary breast cancer Stage IIIIA disease Resected tumor free margin ( i.e. , neoplastic cell resect margin ) Must nodenegative sentinel node complete axillary clearance Axillary clearance require micrometastasis ( 0.2 2 mm ) sentinel node isolated tumor cell Treatment schedule begin within 10 week date surgery Date last surgery take account patient undergoing reexcision positive margin axillary lymph node dissection positive sentinel node biopsy Node positivity node negativity AND ≥ 1 following : T &gt; 2 cm Grade 3 Presence lymphovascular invasion Ki 67 &gt; 20 % Age 35 year Hormone receptor negativity ( &lt; 10 % ) HER2positive tumor ( 3+ IHC FISH+ accord American Society Clinical Oncology guideline [ i.e. , &gt; 2.2 ; case polysomy , ≥ 6 gene copy ] ) Estrogen receptorpositive and/or progesterone receptorpositive disease PATIENT CHARACTERISTICS : Female Pre postmenopausal status Postmenopausal status define ≥ 1 following : At least 60 year age Less 60 year age amenorrheic ≥ 12 month prior day 1 Less 60 year age amenorrheic &lt; 12 month prior day 1 luteinizing hormone folliclestimulating hormone value within postmenopausal range OR without uterus Prior bilateral oophorectomy Prior radiation castration amenorrhea ≥ 6 month ECOG performance status 01 Suitable adjuvant chemotherapy WBC &gt; 3,000/mcL ANC &gt; 1,500/mcL Platelet count &gt; 100,000/mcL Total bilirubin normal AST ALT 2.5 time upper limit normal Creatinine normal Cardiac ejection fraction normal measure ECHO MUGA scan Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study therapy No contraindication anthracycline , cyclophosphamide , fluorouracil , paclitaxel , trastuzumab ( Herceptin® ) treatment No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics See Patient Characteristics No prior chemotherapy , endocrine therapy , radiotherapy No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>